U.S. markets closed

FS Development Corp. II (FSII)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.95-0.05 (-0.50%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close10.00
Bid9.95 x 1800
Ask9.97 x 800
Day's Range9.95 - 10.05
52 Week Range9.85 - 11.17
Avg. Volume67,792
Market Cap256.3M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for FSII

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • FS Development Corp. II
    KLIC: Lowering target price to $58.00KULICKE & SOFFA INDUSTRIES has an Investment Rating of HOLD; a target price of $58.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
  • GlobeNewswire

    Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections

    CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19. PBI-0451 works by inhibiting Viral Main Protease (Mpro), a highly conserved key protein in the virus required for its r

  • GlobeNewswire

    Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors

    CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, today announced the appointments of Deborah M. Autor and Laura J. Hamill to its Board of Directors. “I am thrilled to welcome Deb and Laura to our Board. Both bring extensive and unique industry experience to Pardes, as we prepare for the next stage in our company’s


    SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of FS Development Corp. II (Nasdaq - FSII)

    BALA CYNWYD, PA / ACCESSWIRE / June 29, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of FS Development Corp. ("FSII" or the "Company") (Nasdaq:FSII) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which FSII, a special purpose acquisition company, will combine withPardes Biosciences, Inc.